Christopher Mader

Mader Christopher Ar0xqw

Broad Institute of MIT and Harvard

Senior Group Leader

Christopher Mader currently works as a Senior Group Leader in the Cancer Program at the Broad Institute of MIT and Harvard, where he is leading the effort to industrialize the PRISM cancer cell line screening method to conduct multiplexed cell based screening efforts of unprecedented scale at the Broad. He is currently leading a multidisciplinary team to conduct a large novel anti-cancer small molecule screen as well as collaborating on large-scale drug repurposing efforts. Additional efforts include collaborating with the Broad’s Center for the Development of Therapeutics (CDoT) to develop a new rapid and cost-effective version of PRISM as a tool for chemists and biologists during the drug optimization and development process.

Mader received his B.S. degree in biological sciences from the University of Notre Dame and completed his Ph.D. at Yale University in the Department of Cell Biology in the laboratory of Prof. Anthony J. Koleske, where he studied non-receptor tyrosine kinase signaling pathways that directly regulates invasion and metastasis of breast cancer. He conducted his postdoctoral work in nanotechology in laboratory of Chad Mirkin at Northwestern University, focusing on the development of nanoparticle constructs for the delivery of oligonucleotide payloads for research tools and therapeutic applications.

Prior to joining the Broad in 2014, Mader was a research scientist at AuraSense Therapeutics, where he was the lead biologist for the development of the spherical nucleic acid (SNA) nanoparticle-based gene-regulation therapy for cancer therapeutics and antibiotics. In addition, Mader helped commercialize and tech transfer a live cell RNA detection tool, which was licensed to EMD/Merck Millipore under the SmartFlare brand.

Mader has been recognized for his work with a National Science Foundation Graduate Research Fellowship, a George Robert Pfeiffer Fellowship for Translational Medicine, an American Association for the Advancement of Science (AAAS) Program for Excellence in Science Award, and the Harry Burr Ferris Prize for Distinguished Doctoral Dissertation in Cell Biology at Yale. He was a national finalist for the Council of Graduate Schools National Dissertation Award and was named a fellow of the International Institute for Nanotechnology. He has contributed to 12 manuscripts and 7 patents with over 500 citations in the field of cancer, cell biology, and therapeutics.